Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Desloratadine: a nonsedating antihistamine.

Lynn Limon1, Denise R Kockler

  • 1Department of Pharmacy Services, Virginia Commonwealth University Health System, Medical College of Virginia Hospitals and Physicians, Richmond, VA 23298-0042, USA. llimon@hsc.vcu.edu

The Annals of Pharmacotherapy
|January 29, 2003
PubMed
Summary

Desloratadine is an effective treatment for allergic rhinitis and chronic idiopathic urticaria. However, this nonsedating antihistamine shows no significant advantages over other second-generation options.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.

The Annals of pharmacotherapy·2010
Same author

Plerixafor: a peripheral blood stem cell mobilizer.

Pharmacotherapy·2010
Same author

Probiotics for maintaining remission of ulcerative colitis in adults.

The Annals of pharmacotherapy·2010
Same author

Aromatase inhibitors for ovulation and pregnancy in polycystic ovary syndrome.

The Annals of pharmacotherapy·2009
Same author

Erythropoiesis-stimulating agents: creation and validation of a computerized prescriber order entry alert.

The Annals of pharmacotherapy·2009
Same author

Topiramate for alcohol dependence.

The Annals of pharmacotherapy·2008

Area of Science:

  • Pharmacology
  • Allergy and Immunology

Background:

  • Desloratadine is a nonsedating antihistamine.
  • It is approved for specific allergic conditions.

Purpose of the Study:

  • To review available information on desloratadine.
  • To assess its efficacy and safety profile.

Main Methods:

  • Conducted a MEDLINE search from 1966 to July 2002.
  • Reviewed references and included placebo-controlled, double-blind trials.
  • Utilized unpublished data provided by Schering Corporation.

Main Results:

  • Desloratadine is approved for seasonal allergic rhinitis (SAR), perennial allergic rhinitis (PAR), and chronic idiopathic urticaria (CIU) in patients aged 12 years and older.

Related Experiment Videos

  • Demonstrated superior efficacy in placebo-controlled trials for once-daily treatment of SAR, PAR, and CIU.
  • Evidence suggests anti-inflammatory and decongestant properties.

    • Conclusions:

    • Desloratadine is considered a "me-too" drug.
    • No significant differences were found compared to other second-generation antihistamines.